Brief: Halozyme, Acumen Pharmaceuticals Enter Non-Exclusive License Agreement for ENHANZE Technology in Alzheimer's Disease

Acumen Pharmaceuticals

06/11/2023 12:33

Nov 6 (Reuters) - Halozyme Therapeutics Inc  HALO.O :
    * HALOZYME AND ACUMEN PHARMACEUTICALS ENTER GLOBAL
COLLABORATION
AND NON-EXCLUSIVE LICENSE AGREEMENT FOR THE ENHANZE® TECHNOLOGY
IN ALZHEIMER'S DISEASE
    * HALOZYME THERAPEUTICS INC: ACUMEN WILL MAKE AN UPFRONT
PAYMENT
TO HALOZYME
    * HALOZYME THERAPEUTICS INC: HALOZYME WILL ALSO BE ENTITLED
TO
SINGLE DIGIT ROYALTIES ON NET SALES OF COMMERCIALIZED MEDICINES
WITH ENHANZE TECHNOLOGY
    * HALOZYME: ACUMEN WILL ALSO MAKE POTENTIAL FUTURE MILESTONE
PAYMENTS RELATED TO DEVELOPMENT PROGRESS, REGULATORY APPROVALS,
AND SALES ATTAINMENT TO CO

Source text for Eikon:  ID:nPn2WSvp1a 
Further company coverage:  HALO.O 

 ((Reuters.Briefs@thomsonreuters.com;))